查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918189

去矿骨基质市场－2026-2031年预测

Demineralized Bone Matrix Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计脱矿骨基质市场将从 2025 年的 12.24 亿美元成长到 2031 年的 16.38 亿美元，复合年增长率为 4.98%。

脱矿骨基质（DBM）市场在更广泛的骨生物製药和移植骨替代物产业中占据着重要的细分市场。 DBM是一种同种异体移植材料，由人类骨加工而成，去除了矿物质成分，但保留了其骨诱导蛋白和胶原蛋白结构。它在骨重组中用作骨缺损填充材和生物增强剂，占据了纯粹的骨传导性合成材料和更复杂的细胞骨移植材料之间的重要市场地位。

核心产品特性与临床证据

脱钙骨基质（DBM）的主要价值在于其骨诱导潜能，即诱导宿主干细胞分化为具有成骨潜能的成骨细胞的能力。这种生物活性源自于其保留的骨形成蛋白（BMP）和生长因子，使其有别于惰性骨移植替代材料。其脱矿质且柔韧的特性使其能够适应复杂的骨缺损形状。在临床上，DBM被用作多种手术中的移植填充物或增强剂，尤其是在脊椎融合手术、骨折不癒合以及牙科和颅颚颜面重组中，它在促进自然癒合过程中发挥着重要作用。

主要市场成长驱动因素

推动市场扩张的一个重要人口因素是全球人口老化。老年人罹患骨质疏鬆症、退化性关节疾病和脆性骨折的比例较高，这些疾病都会导致整形外科手术和脊椎融合手术数量的增加。这种老化趋势将导致需要骨移植解决方案以实现骨癒合的患者群体持续成长，从而推动对脱钙骨基质（DBM）作为生物补充剂的稳定需求。

同时，骨骼相关疾病和损伤的发生率不断上升，以及患者对功能恢復的期望日益提高，都推动了外科手术数量的增长。诸如脊髓退化、骨折不癒合以及创伤或肿瘤切除后严重的骨缺损等疾病，需要使用能够积极促进癒合的植入材料，这就支持了骨诱导剂（例如脱钙骨基质）的应用。

该领域的技术和工艺进步是推动成长的关键因素。创新主要集中在提高脱钙骨基质（DBM）产品的一致性、生物活性和操作特性。这包括改进供体筛检、增强加工技术以维持生长因子的功效，以及开发专用载体配方（例如凝胶、糊剂、条带），从而方便外科医生使用并确保产品在手术部位的保留。将DBM与合成支架和其他生物製药结合，以製备最佳化的复合移植物，也是未来发展的重要驱动因素。

DBM的市场地位得益于其在医院环境中持续高水平的手术量，尤其是在脊椎融合手术和复杂整形外科翻修手术领域。医院之所以成为这些手术的中心场所，是因为其拥有完善的手术通讯协定、辅助技术（例如影像、导航）以及与高成本的替代方案相比，基于同种异体移植的手术通常享有更优惠的报销途径。

主要应用领域：脊柱和牙科

两个应用领域特别突出：脊椎融合手术是其核心市场，脱钙骨基质（DBM）被广泛用作自体骨增强或替代材料，以促进后外侧融合术和椎间融合术中的关节融合。 DBM已融入退化性脊椎疾病的标准手术流程，这为其临床应用提供了支持。

牙科是脱钙骨基质（DBM）的另一个主要且快速成长的应用领域。在口腔颚颜面外科中，DBM用于齿槽嵴保存术（为植入做准备）、拔牙后的齿槽窝移植以及鼻窦增高术术。其促进这些部位高品质骨再生的生物学特性备受重视，且易于使用，使其成为牙科手术的理想选择。

区域趋势

北美在脱钙骨基质（DBM）市场保持主导地位。这项优势归功于该地区择期整形外科和脊椎手术数量庞大、组织库和同种异体移植处理基础设施完善、报销政策优惠，以及外科医生对先进生物材料的早期应用。该地区先进的医疗保健生态系统为供需双方提供了支援。

亚太地区被公认为高成长市场，具有巨大的扩张潜力。这主要得益于医疗基础设施的改善、医疗旅游业的蓬勃发展、先进外科技术的日益普及以及人口大国医疗支出的成长。各国政府为推动医疗设备监管现代化和吸引外资所做的努力，也进一步促进了该地区的市场发展和本地製造能力的提升。

竞争格局与策略重点

竞争环境包括专业的骨生物製药公司、设有生物製药部门的大型整形外科器械製造商、组织处理机构。竞争对手专注于产品系列的广度、骨诱导性的稳定性、载体技术，并透过专业的销售和医学教育团队与外科医生建立牢固的关係。

公司策略重点在于透过独特的加工方法、组合产品（例如，添加干细胞或合成颗粒的脱钙骨基质）以及获取临床数据来支持其促进骨骼癒合的功效，从而实现产品差异化。此外，公司也正在投资优化从组织捐赠到成品分销的供应链，以确保可靠性和规模化。

未来市场趋势

脱钙骨基质（DBM）市场的未来发展方向将着重于产品的进一步优化和实证应用。持续的研究将有助于更精确地量化和标准化不同DBM製剂的骨诱导潜能，从而实现更可预测的性能。递送系统和组合产品的创新将解决在复杂手术部位的操作和保留难题。

骨移植替代材料的市场竞争格局也对其产生影响，其中包括合成替代材料和其他先进的生物製剂。脱钙骨基质（DBM）的地位将取决于其能否继续在复杂的骨癒合过程中发挥基础构建模组的作用，同时在常规手术中展现出经济高效的生物增强效果。作为一种成熟的主流生物材料，DBM有望实现稳定成长，这得益于人口结构的变化趋势以及其在整形外科、脊椎外科和牙科等骨缺损外科治疗中的重要作用。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在动态环境中製定策略决策，发展新的业务流和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

它是用来做什么的？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 脱矿骨基质市场（依产品划分）

  • 介绍
  • 凝胶
  • 油灰
  • 贴上
  • 移植材料
  • 其他的

6. 按材料分類的脱矿骨基质市场

  • 介绍
  • 人类骨基质
  • 动物源性骨基质
  • 合成DBM

7. 按应用分類的去矿骨基质市场

  • 介绍
  • 脊椎融合手术
  • 牙科/颚颜面外科
  • 创伤外科
  • 关节重组
  • 其他的

8. 依最终用户分類的去矿骨基质市场

  • 介绍
  • 医院
  • 整形外科诊所
  • 门诊手术中心
  • 其他的

9. 各地区去矿骨基质市场

  • 介绍
  • 北美洲
    • 副产品
    • 材料
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 副产品
    • 材料
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 副产品
    • 材料
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 副产品
    • 材料
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 副产品
    • 材料
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Medtronic plc
  • Zimmer Biomet Holdings, Inc.
  • Stryker Corporation
  • DePuy Synthes
  • Exactech, Inc.
  • SeaSpine Holdings Corporation
  • Straumann Group
  • NuVasive, Inc.

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616016

Demineralized Bone Matrix Market is forecasted to grow at a 4.98% CAGR, increasing from USD 1.224 billion in 2025 to USD 1.638 billion in 2031.

The demineralized bone matrix (DBM) market represents a significant segment within the broader orthobiologics and bone graft substitutes industry. DBM is an allograft material processed from human bone to remove its mineral content while retaining osteoinductive proteins and collagenous structure. It functions as a bone void filler and biologic enhancer in skeletal reconstruction, occupying a critical niche between purely osteoconductive synthetics and more complex cellular bone grafts.

Core Product Function and Clinical Rationale

DBM's primary value lies in its osteoinductive potential-the ability to stimulate host stem cells to differentiate into bone-forming osteoblasts. This biological activity, derived from retained bone morphogenetic proteins (BMPs) and growth factors, differentiates it from inert bone graft extenders. Its demineralized, pliable form allows for moldability to fit complex defect geometries. Clinically, DBM is utilized as a graft extender or enhancer in a variety of procedures, most notably spinal fusions, fracture non-unions, and dental/craniomaxillofacial reconstructions, where it supports the natural healing cascade.

Primary Market Growth Drivers

Market expansion is underpinned by a powerful demographic driver: the global aging population. Older adults exhibit a higher prevalence of osteoporosis, degenerative joint disease, and fragility fractures, all of which increase the volume of orthopedic and spinal fusion procedures. This aging demographic ensures a sustained and growing patient base requiring bone grafting solutions to achieve skeletal union, thereby driving consistent demand for DBM as a biologic adjunct.

Parallel to this, the rising incidence of bone-related disorders and trauma, coupled with increasing patient expectations for functional recovery, bolsters procedural volumes. Conditions such as spinal degeneration, non-healing fractures, and significant bone loss following trauma or tumor resection necessitate grafting materials that actively promote healing, supporting the use of osteoinductive agents like DBM.

Technological and processing advancements within the field are key growth vectors. Innovations focus on enhancing the consistency, bioactivity, and handling characteristics of DBM products. This includes improvements in donor screening, processing techniques to preserve growth factor efficacy, and the development of specialized carrier formulations (e.g., gels, putties, strips) that improve surgeon usability and ensure product retention at the surgical site. Research into combining DBM with synthetic scaffolds or other biologics to create optimized composite grafts also represents a forward-looking driver.

The significant and sustained procedural volume within hospital settings, particularly for spinal fusions and complex orthopedic revisions, consolidates DBM's market position. Hospitals serve as the central hub for these surgeries, driven by established surgical protocols, access to supporting technologies (e.g., imaging, navigation), and often favorable reimbursement pathways for allograft-based procedures compared to higher-cost alternatives.

Key Application Segments: Spine and Dental

Two application segments are particularly prominent. The spinal fusion segment represents a core market, where DBM is extensively used as an autograft extender or substitute in posterolateral and interbody fusions to promote arthrodesis. Clinical adoption is supported by its integration into standard surgical workflows for degenerative spine conditions.

The dental application segment is also a major and growing area of use. In oral and maxillofacial surgery, DBM is employed for alveolar ridge preservation, socket grafting following extraction, and sinus lift procedures in preparation for dental implants. Its biologic properties are valued for promoting quality bone regeneration in these sites, and its availability in easy-to-handle forms makes it well-suited for dental surgical practice.

Geographic Landscape and Regional Dynamics

North America maintains a dominant position in the DBM market. This leadership is attributed to a high volume of elective orthopedic and spinal procedures, a well-established tissue banking and allograft processing infrastructure, favorable reimbursement frameworks, and early surgeon adoption of advanced biologic materials. The region's sophisticated healthcare ecosystem supports both supply and demand.

The Asia-Pacific region is identified as a high-growth market with significant expansion potential. This is driven by improving healthcare infrastructure, rising medical tourism, growing adoption of advanced surgical techniques, and increasing healthcare expenditure in populous countries. Government initiatives to modernize medical device regulations and attract foreign investment further stimulate market development and local manufacturing capabilities in the region.

Competitive Landscape and Strategic Focus

The competitive environment includes specialized orthobiologics companies, large orthopedic device firms with biologics divisions, and tissue processing organizations. Competition centers on product portfolio breadth, consistency of osteoinductive potential, carrier technology, and strong surgeon relationships through dedicated sales and medical education teams.

Strategic initiatives are focused on product differentiation through proprietary processing methods, combination products (e.g., DBM with stem cells or synthetic granules), and securing clinical data to support claims of fusion efficacy. Companies also invest in streamlining supply chains from tissue donation to finished product distribution to ensure reliability and scale.

Future Market Trajectory

The future trajectory of the DBM market is oriented toward greater product refinement and evidence-based application. Continued research will aim to better quantify and standardize the osteoinductive potential of different DBM formulations, moving toward more predictable performance. Innovation in delivery systems and combination products will seek to address limitations in handling and retention in challenging surgical sites.

The market will also be influenced by the competitive landscape of bone graft substitutes, including the growth of synthetic alternatives and other advanced biologics. DBM's position will depend on its ability to demonstrate cost-effective biologic augmentation in routine procedures while continuing to serve as a foundational component in complex bone healing scenarios. As a well-established biologic workhorse, DBM is poised for steady growth, reinforced by demographic trends and its entrenched role in the surgical management of bone defects across orthopedic, spinal, and dental specialties.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Demineralized Bone Matrix Market Segmentation

  • By Product
  • Gel
  • Putty
  • Paste
  • Graft
  • Others
  • By Material
  • Human DBM
  • Animal DBM
  • Synthetic DBM
  • By Application
  • Spinal Fusion
  • Dental / Maxillofacial Surgery
  • Trauma Surgery
  • Joint Reconstruction
  • Others
  • By End-User
  • Hospitals
  • Orthopedic Clinics
  • Ambulatory Surgical Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DEMINERALIZED BONE MATRIX MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Gel
  • 5.3. Putty
  • 5.4. Paste
  • 5.5. Graft
  • 5.6. Others

6. DEMINERALIZED BONE MATRIX MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Human DBM
  • 6.3. Animal DBM
  • 6.4. Synthetic DBM

7. DEMINERALIZED BONE MATRIX MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Spinal Fusion
  • 7.3. Dental / Maxillofacial Surgery
  • 7.4. Trauma Surgery
  • 7.5. Joint Reconstruction
  • 7.6. Others

8. DEMINERALIZED BONE MATRIX MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Orthopedic Clinics
  • 8.4. Ambulatory Surgical Centers
  • 8.5. Others

9. DEMINERALIZED BONE MATRIX MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Material
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Material
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Material
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Material
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Material
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Medtronic plc
  • 11.2. Zimmer Biomet Holdings, Inc.
  • 11.3. Stryker Corporation
  • 11.4. DePuy Synthes
  • 11.5. Exactech, Inc.
  • 11.6. SeaSpine Holdings Corporation
  • 11.7. Straumann Group
  • 11.8. NuVasive, Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations